USANA Health Sciences (USNA) to Release Quarterly Earnings on Tuesday

USANA Health Sciences (NYSE:USNA) is projected to post its quarterly earnings results after the market closes on Tuesday, April 22nd. Analysts expect USANA Health Sciences to post earnings of $0.74 per share and revenue of $243.08 million for the quarter. USANA Health Sciences has set its FY 2025 guidance at 2.350-3.000 EPS.Individual that are interested in registering for the company’s earnings conference call can do so using this link.

USANA Health Sciences (NYSE:USNA) last released its quarterly earnings data on Tuesday, February 25th. The company reported $0.64 EPS for the quarter, beating the consensus estimate of $0.49 by $0.15. The company had revenue of $213.61 million during the quarter, compared to the consensus estimate of $208.82 million. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. On average, analysts expect USANA Health Sciences to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

USANA Health Sciences Trading Up 1.3 %

Shares of USNA opened at $23.75 on Monday. The company has a market cap of $448.90 million, a price-to-earnings ratio of 8.39, a PEG ratio of 0.93 and a beta of 1.00. The company’s fifty day simple moving average is $28.44 and its 200 day simple moving average is $33.53. USANA Health Sciences has a 1-year low of $23.26 and a 1-year high of $49.78.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on USNA shares. DA Davidson dropped their target price on shares of USANA Health Sciences from $38.00 to $36.00 and set a “neutral” rating on the stock in a report on Thursday, February 27th. Sidoti lowered USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 18th. Finally, StockNews.com cut USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, February 14th.

Insider Activity

In other news, CEO Jim Brown sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $29.47, for a total value of $147,350.00. Following the transaction, the chief executive officer now owns 15,716 shares of the company’s stock, valued at approximately $463,150.52. This represents a 24.14 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider David Mulham Mulham sold 3,234 shares of the business’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $32.98, for a total value of $106,657.32. Following the completion of the sale, the insider now owns 12,775 shares of the company’s stock, valued at $421,319.50. This trade represents a 20.20 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 15,920 shares of company stock valued at $500,285 over the last ninety days. 0.63% of the stock is currently owned by company insiders.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.